Sector News

Illumina acquires Edico Genome

May 16, 2018
Life sciences

Illlumina said Tuesday that it has acquired data analysis firm Edico Genome.

Edico markets its DRAGEN platform, which uses field programmable gate array technology in combination with proprietary software algorithms to reduce data footprint and enable faster speeds. Users can run DRAGEN on site, in the cloud or in a hybrid mode, and can use a variety of different cloud storage solutions and analysis pipelines.

“Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,” Susan Tousi, senior vice president of product development at Illumina, said in a statement.

Edico President and CEO Pieter van Rooyen added, “As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing.”

Stephen Kingsmore’s group at Rady Children’s Institute for Genomic Medicine has been using Edico’s DRAGEN to speed up the time-to-diagnosis for its whole-genome sequencing pipeline for critically ill infants in the NICU and has developed a rapid protocol that take just under 24 hours.

Financial details of the acquisition were not disclosed.

Source: genomeweb

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend